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Abstract
Background. A primary tubular sodium handling
abnormality has been implicated in the edema forma-
tion of nephrotic syndrome. Dopamine synthesized
by renal proximal tubules behaves as an endogenous
natriuretic hormone by activating D1-like receptors as
a paracrine/autocrine substance.
Methods. We examined the time courses of the urinary
excretion of sodium, protein and dopamine in puro-
mycin aminonucleoside (PAN)-treated and control
rats. The rats were sacriﬁced during greatest sodium
retention (day 7) as well as during negative sodium
balance (day 14) for the evaluation of renal aromatic
L-amino acid decarboxylase (AADC) activity, the
enzyme responsible for the synthesis of renal dopa-
mine. Also, the inﬂuence of volume expansion (VE)
and the effects of the D1-like agonist fenoldopam
(10 mg/kg bw/min) on natriuresis and on proximal
tubular Naþ,Kþ-ATPase activity were examined on
day 7.
Results. The daily urinary excretion of dopamine
was decreased in PAN-treated rats, from day 5 and
beyond. This was accompanied by a marked decrease
in the renal AADC activity, on days 7 and 14. During
VE, the fenoldopam-induced decrease in proximal
tubular Naþ,Kþ-ATPase activity was more pro-
nounced in PAN-treated rats than in controls.
However, the urinary sodium excretion during fenol-
dopam infusion was markedly increased in control rats
but was not altered in PAN-treated animals.
Conclusion. PAN nephrosis is associated with a
blunted renal dopaminergic system activity which
may contribute to enhance the proximal tubular
Naþ,Kþ-ATPase activity. However, the lack of renal
dopamine appears not to be related with the overall
renal sodium retention in a state of proteinuria.
Keywords: aromatic L-amino acid decarboxylase
(AADC); fenoldopam; Naþ,Kþ-ATPase; nephrotic
syndrome; renal dopamine; sodium handling
Introduction
Evidence has been gathered implicating a primary renal
sodium handling abnormality in the edema formation
of nephrotic syndrome. The nephrotic state was asso-
ciated with enhanced sodium retention in the cortical
collecting duct. It was suggested by Deschenes and
Doucet [1] that the mechanism responsible for the
primary distal sodium retention in nephrotic syndrome
is the combination of a blunted natriuretic response
to atrial natriuretic peptide (ANP) [2] and an enhanced
Naþ,Kþ-ATPase activity in the cortical collecting
duct [3]. The ANP resistance, which occurs after ANP
binding to its receptors in the collecting duct, appears
to result from the activation of a phosphodiesterase
responsible for the catabolism of cyclic guanosine
monophosphate (cGMP), the second messenger of
ANP [4]. On the other hand, a primary sodium
handling abnormality in the proximal tubules has
been invoked recently with the observation that
sodium retention in the nephrotic syndrome may be
associated with a shift of the Naþ/Hþ exchanger NHE3
from the inactive to an active pool [5]. However,
the Naþ,Kþ-ATPase activity in proximal convoluted
tubules was shown not to differ between nephrotic and
control animals [6] and, therefore, the role of the
proximal tubules in the enhanced sodium retention
in the nephrotic syndrome still remains to be fully
elucidated.
The epithelial cells of proximal tubules are endowed
with a high aromatic L-amino acid decarboxylase
(AADC) activity, the enzyme responsible for the
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conversion of circulating or ﬁltered L-3,4-dihydroxy-
phenylalanine (L-Dopa) to dopamine [7]. The renal
dopaminergic system appears to be highly dynamic
and basic mechanisms for the regulation of this
system are thought to depend mainly on the availability
of L-Dopa, its fast decarboxylation into dopamine
and in precise and accurate cell outward amine transfer
mechanisms [7,8]. Dopamine synthesized by the renal
proximal tubules behaves as an endogenous natriuretic
hormone by activating D1-like receptors as a paracrine/
autocrine substance [7,9]. During moderate sodium
surfeit, dopamine of renal origin accounts for 50%
of sodium excretion [8,9]. Renal dopamine decreases
tubular sodium reabsorption by inhibition of Naþ,Kþ-
ATPase activity directly or in response to the decrease
in intracellular sodium following inhibition of Naþ/Hþ
exchanger NHE3 [9,10]. Dopamine of renal origin can
regulate sodium balance also by interaction with other
natriuretic factors such as ANP [8]. In the late 1980s,
several laboratories reported that the natriuretic
response to ANP requires an intact renal dopaminergic
system. More recently, the interaction between ANP
and renal dopamine was further reinforced by the
ﬁndings that ANP and its second messenger, cGMP,
cause a rapid translocation of the D1-like receptors to
the plasma membrane [11].
On the basis of these considerations, this study was
undertaken with the aim to evaluate the role of renal
dopaminergic system in the sodium retention observed
in rats with puromycin aminonucleoside (PAN)-
induced nephrotic syndrome. For this purpose, we
examined the time courses of the urinary excretion
of sodium, protein, dopamine, the precursor L-Dopa
and metabolites (3,4-dihydroxyphenylacetic acid,
DOPAC and homovanillic acid, HVA) in PAN-treated
and control rats. The rats were sacriﬁced on days 7
and 14 for the evaluation of the renal AADC activity.
Also, the inﬂuence of volume expansion and the
effects of the D1-like receptor agonist fenoldopam on
sodium excretion and on proximal tubular Naþ,Kþ-
ATPase activity were examined during the phase of
greatest sodium retention and ascites accumulation
(day 7).
Materials and methods
In vivo studies
PAN-induced nephrosis. Normotensive male Sprague–
Dawley rats (Harlan, Barcelona, Spain), weighing 200–220 g,
were selected after a 7-day period of stabilization
and adaptation to blood pressure measurements. The
animals received a single intraperitoneal injection of
10ml/kg bw of PAN (150mg/kg bw) or the vehicle (NaCl
0.9%) on day 0.
Metabolic studies. The animals were kept under controlled
environmental conditions (12:12 h light/dark cycle and room
temperature 22±2C); ﬂuid intake and food consumption
were monitored daily throughout the study. Two days before
the PAN or vehicle injection, the rats were placed in metabolic
cages (Techniplast, Buguggiate-VA, Italy). The PAN and
control rats had free access to tap water. The PAN-treated
rats were fed ad libitum throughout the study with ordinary
rat chow (Panlab, Barcelona, Spain) containing 1.9 g/kg
of sodium. In order to achieve the same daily sodium intake
between the two groups, the control rats had only access to
the mean daily rat chow intake of the PAN-treated animals.
Twenty-four hour urine was collected, on even days in
empty vials for later determinations of sodium, protein and
creatinine and on uneven days in vials containing 1ml
hydrochloric acid 6M (to avoid the spontaneous oxidation
of the amines and its derivatives) for later determination
of catecholamines. Urine volume was gravimetrically deter-
mined. Blood pressure (systolic and diastolic) and heart
rate were measured daily throughout the study in conscious
restrained animals, between 7.00 and 10.00 AM, using a
photoelectric tail-cuff pulse detector (LE 5000, Letica,
Barcelona, Spain).
Animals were sacriﬁced on day 7 and on day 14 after
injection. On the days of sacriﬁce the animals were
anaesthetized with pentobarbital sodium (50mg/kg bw; i.p.)
and the ascites volumes were measured through moistening
and weighing an absorbent paper. Blood was collected
from the heart in tubes containing heparin and lithium/
heparin for later determination of plasma catecholamines
and biochemical parameters, respectively. The kidneys were
rapidly removed, weighed and the outer cortex isolated.
Fragments of renal cortex were used for later determination
of AADC activity. Other fragments of renal cortex, weighing
200mg, were placed in vials containing 1ml of 0.2M
perchloric acid, stored at 80C until quantiﬁcation of
catecholamines by HPLC with electrochemical detection.
Segments of jejunum, 10 cm in length, were also removed,
opened longitudinally with ﬁne scissors and rinsed free from
blood and intestinal contents with cold saline; thereafter, the
jejunal mucosa was removed with a scalpel for later
determination of AADC activity.
Volume expansion. In another set of experiments, 7 days
after PAN or vehicle injection, the animals were anaesthetized
with pentobarbital sodium (50mg/kg bw followed by 20mg/
kg bw/h; i.p.) and were subjected to volume expansion (VE)
with saline (0.9% NaCl) through a catheter in the jugular
vein, as previously reported [12]. The infusion of fenoldopam
(10mg/kg bw/min) or the vehicle (0.9%NaCl) started at a rate
of 5ml/kg bw/h for 120min; during this period two con-
secutive 60min urine samples were collected (t¼ 0–120min,
basal). After this stabilization period the VE was started
increasing the infusion to a rate of 50ml/kg bw/30min
(5% body weight, t¼ 120–150min, VE). Thereafter, the
infusion was again reduced to 5ml/kg bw/h for 90min;
during this recovery period, urine sampling was performed
every 30min until the end of the experiment (t¼ 150–180min,
R-VE1; t¼ 180–210min, R-VE2 and t¼ 210–240min, R-
VE3). The urine was collected in empty vials for later
determinations of sodium and creatinine and in another
set of experiments the urine was collected in vials containing
50 ml of hydrochloric acid 6M for later determination
of dopamine. Because the dopamine assay requires higher
urine volumes, the recovery periods 2 and 3 were collected
jointly. At the end of this protocol the animals
were euthanized and the kidneys were removed for later
determination of Naþ,Kþ-ATPase activity in proximal
tubular cells.
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In vitro studies
AADC activity. Fragments of renal cortex and jejunal
mucosa were homogenized at 4C with a Thomas Teﬂon
homogenizer (Poliscience Corp., IL, USA) in the incubation
medium containing (in mM): 0.35 NaH2PO4, 0.15 Na2HPO4,
0.11 Na2B4O7 and 0.2 pyridoxal phosphate (pH 7.0).
Tolcapone (1 mM) and pargyline (100mM) were added to
the incubation medium in order to inhibit the metabolization
of dopamine by catechol-O-methyltransferase (COMT) and
monoamine-oxidase (MAO), respectively. Activity of AADC
was determined as previously described by Soares-da-Silva
[12] using L-Dopa (0.1–10mM) as substrate. The assay
of dopamine was performed by HPLC with electro-
chemical detection. The protein content in cell suspension
(1.5mg/ml) was determined by the Bradford method [13].
Naþ,Kþ-ATPase activity. Naþ,Kþ-ATPase activity was
measured by the method of Quigley and Gotterer [14] adapted
in our laboratory with slight modiﬁcations. The rat renal
proximal tubules were isolated, as previously described [15].
In brief, a ﬁne paste of outer cortex was prepared and
ﬁltered sequentially through a series of Nybolt nylon sieves,
ﬁrst 180 mm and then 75 mm. The renal proximal tubules were
retained in the 75 mm sieve and were then washed off with
cold Collins solution and collected into a pellet by centrifuga-
tion at 200 g, 5min, 4C. Renal tubules used in incubation
experiments were suspended in Hanks’ medium. The
Naþ,Kþ-ATPase activity was determined in conditions of
saturating sodium and tris salt adenosine 50-triphosphate
(ATP) concentration. The isolated renal proximal tubules
were pre-incubated for 10min at 37C followed by rapid
freezing at 80C and subsequent thawing to allow cell
permeabilization. The reaction mixture, in the ﬁnal volume of
1.025ml, contained (in mM): 37.5 imidazole buffer, 75 NaCl,
5 KCl, 1 sodium EGTA, 5 MgCl2, 75 NaN3, 75 tris(hydroxy-
methyl)aminomethane(tris) hydrochloride and 100ml cell
suspension. For the determination of ouabain-resistant
ATPase, NaCl and KCl were omitted, and Tris-HCl
(150mM) and ouabain (1mM) were added to the assay.
The reaction was initiated by addition of 4mM ATP. After
incubation at 37C for 20min, the reaction was terminated
by the addition of 50ml of ice-cold trichloroacetic acid. The
samples were centrifuged (4000 rpm) and liberated Pi in the
supernatant was measured as the result of ATPase activity.
The assay of Pi was performed by spectrophotometry.
Ouabain-sensitive ATPase activity is expressed as nanomoles
of Pi per miligram of protein per minute and determined as
the difference between total and ouabain-resistant ATPase.
The protein content in cell suspension (1.1mg/ml) was
determined by the Bradford method [13]. The relationship
between the incubation time and Naþ,Kþ-ATPase activity
was linear between 5 and 40min. In addition, the relation-
ship between protein content in cell suspension and
Naþ,Kþ-ATPase activity was linear between 0.4 and
1.3mg/ml.
Assay of catecholamines. The assay of catecholamines
and its metabolites in urine, plasma samples, renal tissues
and in samples fromAADC studies were performed byHPLC
with electrochemical detection, as previously described [16].
In our laboratory, the lower limit of detection of L-Dopa,
dopamine, DOPAC and HVA ranged from 350 to 1000 fmol.
Plasma and urine ionogram and biochemistry. Ion-
selective electrodes performed the quantiﬁcations of sodium
in plasma and urine samples. Urea was measured by an
enzymatic test and creatinine by the Jaffe´ method. Total
proteins were determined by a colorimetric test, the biuret
reaction. All assays were performed by Cobas Mira Plus
analyser (ABX Diagnostics, Switzerland). Creatinine clear-
ance was calculated using 24 h urinary creatinine excretion.
Fractional excretion of sodium (FENaþ) was calculated as
previously reported [12]. Sodium balance was determined
subtracting the absolute daily urinary sodium excretion
(mmol/24 h) to daily sodium intake (mmol/24 h).
Drugs. The compounds ATP, DOPAC, dopamine hydro-
chloride, HVA, L-Dopa, ouabain, PAN, pargyline hydro-
chloride and fenoldopam were obtained from Sigma
(St Louis, MO, USA). Tolcapone was kindly donated by
the late Professor Mose´ Da Prada (Hoffmann-La Roche,
Basel, Switzerland).
Statistics. Results are means±SE of values for the
indicated number of determinations. Maximal velocity
(Vmax) and Micha¨elis–Menten coefﬁcient (Km) for AADC
enzymatic assay were calculated from non-linear regression
analysis using GraphPad Prism statistics software package
[17] and compared by one-way ANOVA followed by
Student’s t-test for unpaired comparisons. P<0.05 was
assumed to denote a signiﬁcant difference.
Results
PAN nephrosis—renal function and sodium handling
The sodium intake was similar in both PAN-treated
and control animals throughout the study since the
control animals had the same food intake as PAN-
treated rats (Table 1). As shown in Figure 1, the PAN-
treated rats developed severe proteinuria on day 4 and
beyond reaching a plateau on day 8 whereas the renal
protein excretion was minimal in control animals
throughout the study. In parallel, the PAN-treated
rats showed a marked decrease in urinary sodium
excretion compared with control animals from day 2
to day 8 after drug administration (Figure 1), followed
by an increase in the urinary excretion of sodium from
days 12 to 14. On day 7 after injection, the PAN-treated
rats exhibited a reduced FENaþ accompanied with
marked ascites whereas on day 14 after injection the
PAN-treated rats presented an increased FENaþ
accompanied with ascites of much smaller magnitude
(Table 1). The body weight was greater in PAN-treated
rats than in control animals from day 5 to day 10
(Figure 1), showing that in PAN nephrosis the animal
weight is a good index of ascites accumulation. Taken
together, PAN administration resulted in the clinical
equivalent of nephrotic syndrome with persistent
proteinuria as well as sodium and volume retention
up to day 8 after drug injection [1]. The creatinine
clearance was lower in PAN-treated than in control rats
either on day 7 or on day 14 (Table 1). Systolic and
diastolic blood pressure did not differ signiﬁcantly
between nephrotic and control rats throughout the
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study (Table 1). Plasma levels of sodium were similar
between the two groups either on day 7 or day 14
(Table 1). Plasma levels of urea nitrogen were increased
in PAN-treated rats on day 7 whereas plasma levels
of creatinine were increased in nephrotic rats on both
days 7 and 14 after drug injection (Table 1). Plasma
protein concentration was reduced in PAN-treated rats
on day 7 (Table 1).
Renal dopaminergic activity
The urinary levels of dopamine were transiently
increased in PAN-treated rats during the ﬁrst day
after drug injection; this was followed by 60%
reduction in urinary levels of dopamine on day 5 and
beyond (Figure 2). By contrast, the urinary excretion
of the dopamine precursor, L-Dopa, did not differ
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Fig. 1. Body weight, urinary proteins and urinary excretion of sodium in PAN and control rats throughout the study. Symbols
represent means of 12 rats per group and error bars represent SE. *P<0.05, **P<0.01, ***P<0.001, signiﬁcantly different from values in
control rats.
Table 1. Body weight, metabolic balance and renal function in PAN-treated and control rats 7 and 14 days after injection
Day 7 Day 14
Control PAN Control PAN
Body weight, g 221±5 248±4* 241±2 234±5
Creatinine, ml/min 5.65±1.38 2.24±0.81* 4.51±1.08 2.24±0.32*
Plasma creatinine, mg/dl 0.20±0.02 0.54±0.06* 0.22±0.02 0.32±0.03*
Plasma urea, mg/dl 43±2 143±13* 41±2 43±2
Plasma proteins, g/l 46±1 36±1* 49±2 49±3
Plasma Naþ, mmol/l 137±1 136±1 135±3 135±1
Naþ intake, mmol/24 h 1.07±0.01 0.96±0.06 1.31±0.05 1.47±0.33
Naþ excretion, mmol/24 h 1.11±0.06 0.07±0.02* 1.13±0.13 2.08±0.29*
Naþ balance, mmol/24 h 0.03±0.07 0.90±0.07* 0.18±0.13 0.61±0.38*
FENaþ, % 0.14±0.01 0.04±0.01* 0.17±0.03 0.53±0.14*
Ascites, g 0.7±0.1 14.5±1.1* 0.6±0.1 1.3±0.3*
Systolic BP, mmHg 155±8 147±6 138±4 150±7
Diastolic BP, mmHg 106±9 86±8 86±3 86±7
Heart rate, beats/min 423±8 390±16 406±9 387±37
Values are means±SE; n¼ 8 to 12 experiments per group. Creatinine¼ creatinine clearance, FE¼ fractional excretion and BP¼ blood
pressure. *P<0.05, signiﬁcantly different from corresponding values in control rats.
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between the PAN-treated rats and control animals
throughout the study (Figure 2). These data suggest
that the nephrotic rats might have a reduced ability
to synthesize dopamine in renal proximal tubules. In
agreement with this view are the results from studies
evaluating the activity of AADC, the enzyme respon-
sible for the synthesis of renal dopamine. The activity
of AADC was determined in homogenates of renal
cortex using L-Dopa as substrate, which resulted in
a concentration-dependent formation of dopamine
(Figure 3). The Vmax values for AADC activity in
renal cortex were found to be signiﬁcantly lower in
PAN-treated rats than in control animals on either
day 7 or day 14 (Table 2); the decarboxylation reaction
was a saturable process with Km values of the same
magnitude in the two groups (Table 2). In experiments
performed with jejunal mucosa homogenates, no
signiﬁcant differences were observed in AADC activity
between PAN-treated and control rats (Table 2).
Similar to that observed with urinary dopamine,
the urinary excretion of the deaminated metabolite
DOPAC was transiently increased in PAN-treated rats
on day 1, followed by 50% reduction on day 5 and
beyond (Figure 4). By contrast, the urinary excretion
of the deaminated plus methylated metabolite, HVA,
did not differ between the two groups of rats
throughout the study (Figure 4).
Since the purpose of our study was to evaluate the
possible role of the renal dopaminergic system in the
sodium retention observed in PAN nephrosis, we
examined the relationship between urinary dopamine
and sodium excretion and found no linear relation
between the two parameters (r2¼ 0.06) throughout the
study. Also, no linear relationship was observed
between urinary DOPAC and urinary sodium excretion
(r2¼ 0.01) throughout the study.
Notwithstanding the differences observed in urinary
levels of dopamine as well as in the renal AADC
activity between the two experimental groups, the
plasma and renal tissue levels of dopamine and the
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Fig. 2. Urinary levels of dopamine and L-Dopa in PAN and control rats throughout the study. Symbols represent means of 12 rats per
group and error bars represent SE. *P<0.05, ***P<0.001, signiﬁcantly different from values in control rats.
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precursor L-Dopa did not differ between the PAN-
treated and control animals, either on day 7 or day 14
(Table 3).
Volume expansion and assessment of D1
receptor-mediated natriuresis
The urinary dopamine excretion was markedly
increased by 130% both during and after VE in control
rats, whereas in PAN-treated animals the urinary
dopamine output did not increase signiﬁcantly either
during or after VE (Figure 5). This resulted in the
urinary dopamine excretion being markedly lower in
PAN-treated rats than in control animals, before
(basal), during and after VE (Figure 5). The urinary
sodium excretion was markedly lower in PAN-treated
rats than in control animals before (basal, P<0.05),
during (VE, P<0.01) and after (R-VE1, P<0.0001;
R-VE2, P<0.0001; R-VE3, P<0.0001) VE in vehicle-
treated rats (Figure 6). Fenoldopam induced a 20–80%
increase in the accumulated urinary sodium excretion
in control rats whereas the D1 receptor agonist did not
signiﬁcantly change the urinary sodium excretion in
PAN-treated animals throughout the study (Figure 6).
Fenoldopam did not alter the urinary dopamine
excretion in either control or PAN-treated rats
throughout the study (data not shown).
Renal proximal tubular Naþ,Kþ-ATPase activity
The Naþ,Kþ-ATPase activity in renal proximal tubules
was determined in PAN-treated and control rats after
VE with the infusion of fenoldopam or the vehicle.
As shown in Figure 7, the Naþ,Kþ-ATPase activity
after vehicle infusion did not differ between PAN-
treated and control rats. The effect of the dopamine D1
receptor agonist infusion was a decrease in Naþ,Kþ-
ATPase activity in both groups, which was more
pronounced in PAN-treated rats than in control
animals (49±6% vs 31±4%, P<0.05).
Discussion
The present study was undertaken with the aim of
clarifying the possible role of the renal dopaminergic
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Table 2. Kinetic parameters (Vmax and Km) of AADC activities in homogenates of renal cortex and jejunal mucosa from PAN-treated
and control rats 7 and 14 days after injection
Day 7 Day 14
Control PAN Control PAN
Renal cortex
Vmax, nmol/mg prot/15min 234±13 159±14* 218±15 134±10*
Km, mM 2.8±0.2 2.1±0.1 2.5±0.2 2.8±0.2
Jejunal mucosa
Vmax, nmol/mg prot/15min 105±10 105±24 103±5 83±11
Km, mM 2.5±0.1 2.2±0.2 2.9±0.2 2.5±0.3
Values are means±SE; n¼ 7–12 experiments per group. *P<0.01, signiﬁcantly different from corresponding values in control rats.
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system in the renal sodium retention of the nephrotic
syndrome. Our results provided evidence for a mark-
edly reduced renal dopamine synthesis in PAN-treated
rats. The enhanced proximal Naþ,Kþ-ATPase sensi-
tivity to inhibition by fenoldopam observed in PAN-
treated rats suggests that the lack of renal dopamine
may contribute to increase the proximal tubular
sodium absorption in PAN nephrosis. However, the
reduced renal dopaminergic activity appears not to be
an important mechanism related to the overall renal
sodium retention in PAN nephrosis because: (1) the
decrease in sodium excretion in PAN-treated rats
preceded the decrease in urine dopamine output; (2)
no correlation was observed between urine dopamine
output and sodium excretion (or sodium balance)
throughout the study; and (3) a blunted natriuretic
response to the infusion of fenoldopam was observed
in PAN-treated rats during greatest sodium retention
and ascites accumulation.
As previously reported [1], the urinary protein
excretion increased 4 days after injection of PAN and
remained elevated throughout the duration of the
study. In addition, the time courses of variations of
sodium retention and ascites accumulation in PAN
nephrosis were divided into two phases. The ﬁrst phase,
from day 2 to day 8, was marked by the decrease of
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Fig. 6. Accumulated urinary sodium excretion in vehicle-treated
and fenoldopam-treated (10 mg/kg bw/min) PAN (A) and control
(B) rats before (t¼ 0–120min, Basal), during (t¼ 120–150min, VE)
and after (t¼ 150–180min, R-VE1; t¼ 180–210min, R-VE2;
t¼ 210–240, R-VE3) volume expansion, 7 days after injection.
Bars represent means of 6–12 experiments per group and error
bars represent SE. *P<0.05, **P<0.01, ***P<0.001, signiﬁcantly
different from values in vehicle-treated rats.
Table 3. Levels of dopamine and L-Dopa in plasma and in renal cortex of PAN-treated and control rats 7 and 14 days after injection
Day 7 Day 14
Control PAN Control PAN
Plasma levels
Dopamine 0.89±0.10 0.87±0.15 0.87±0.19 0.61±0.12
L-Dopa 6.08±0.47 5.30±0.32 6.05±0.37 6.16±1.16
Renal cortex levels
Dopamine 44.7±3.7 58.4±17.0 37.6±6.7 29.4±9.1
L-Dopa 73.2±15.5 77.9±13.7 102.3±18.3 103.8±19.0
Values are means±SE; n¼ 5–12 experiments per group. Values are expressed for plasma in picomoles per millilitre and for renal cortex in
picomoles per gram.
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control rats before (t¼ 0–120min, Basal), during (t¼ 120–150min,
VE) and after (t¼ 150–180min, R-VE1; t¼ 180–240min, R-
VE2þ3) volume expansion, 7 days after injection. Bars represent
means of 5–6 experiments per group and error bars represent SE.
*P<0.05, **P<0.01, ***P<0.001, signiﬁcantly different from
values in control rats; #P<0.05, ###P<0.001, signiﬁcantly
different from basal levels in corresponding group of rats.
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sodium excretion accompanied with positive sodium
balance and ascites accumulation. The second phase,
from days 10 to 14, was marked by almost complete
recovery of ascites, despite persistent high proteinuria.
During this phase, urinary sodium excretion increased
progressively towards higher than control levels from
days 12 to 14, so that sodium balance was negative
during this period. Thus, the appearance of proteinuria
in PAN-treated rats did not inﬂuence the course of
urinary sodium excretion. This dissociation between
proteinuria and urinary sodium excretion was
reported previously in PAN-treated and other nephro-
tic syndrome rat models [1] and supports the hypothesis
that the reduction of urinary sodium excretion may
be independent of the development of proteinuria
and may be, instead, attributable to a tubular disorder
independent of glomerular events.
The combined data of our study point to a marked
decrease in renal dopaminergic system activity in
both phases of PAN nephrosis. The reduced renal
dopaminergic system activity in PAN-treated rats was
evidenced by low AADC activity (on both days 7 and
14) and low urinary levels of dopamine, from day 5
and beyond. Renal dopamine synthesis is supposed to
be mainly inﬂuenced by the: (1) total number of well
functioning tubular units endowed with AADC; (2)
renal delivery of sodium and L-Dopa; and (3) activity
of AADC in proximal tubular cells [7]. Given that
the creatinine clearance is a rough measure of the total
number of well functioning nephrons, the reduced
creatinine clearance observed in PAN-treated rats
suggests that a decreased delivery of sodium to a
reduced number of well-functioning tubular units may
contribute to the decrease in urine dopamine excre-
tion in PAN-treated rats. Taken together, our results
suggest that the reduced urinary dopamine excretion in
PAN nephrosis is mainly related to (1) reduced number
of well-functioning nephrons; (2) reduced tubular
delivery of sodium; and (3) decreased renal tubular
decarboxylation of L-Dopa to dopamine.
Although puromycin is widely used to induce
proteinuria, evidence has been gathered that PAN has
no selective glomerular effect, but can also damage the
proximal tubules before proteinuria develops [5,18].
Thus, one can hypothesize that the decreased renal
dopamine synthesis and urinary excretion may be
due, at least in part, to PAN tubulotoxicity. Indirect
evidence of such an effect can be derived from Figure 3,
which shows an initial increase in urinary dopamine
excretion, suggesting a release of dopamine from
damaged proximal tubule cells before the increase in
urine protein excretion.
The reduced renal dopamine activity in PAN-treated
rats was not accompanied by changes in the renal tissue
levels of L-Dopa or dopamine. The explanation for this
apparent discrepancy has to do with the nature of this
non-neuronal dopaminergic system [7,8]. The amine
storage structures normally present in monoaminergic
neuronal systems and the classical mechanisms for
the regulation of amine formation and release are not
present or in operation; the basic mechanisms for the
regulation of this system are thought to depend on the
availability of L-Dopa, its fast decarboxylation into
dopamine and in precise and accurate cell outward
amine transfer mechanisms [7,8]. It is interesting to note
that AADC in jejunal epithelial cells failed to change
in PAN-treated rats suggesting that the decrease in
enzyme activity observed in the renal parenchyma
resulted from local effects.
The urinary excretion of DOPAC followed quite
closely the urinary excretion of the parent amine
throughout the study. This suggests that deamination
of dopamine was not compromised in PAN-treated rats
and further supports our previous suggestion that
urinary DOPAC is a good marker of renal production
of dopamine and simultaneously a good index of cell
integrity and viability [19], since MAO is a mitochon-
drial enzyme and is quite sensitive to changes in tissue
oxygen tension. By contrast, the urinary excretion of
HVA did not follow the decrease in the daily urinary
excretion of dopamine and DOPAC in PAN-treated
rats. This agrees well with the suggestion that urinary
HVA has its origin mainly in extrarenal tissues.
Renal dopamine decreases proximal tubular sodium
reabsorption by inhibition of Naþ,Kþ-ATPase activity
directly or in response to the decrease in intracellular
sodium following inhibition of Naþ/Hþ exchanger
NHE3 [9,10]. Thus, one can hypothesize that the
observed reduced renal dopamine tonus in rats with
PAN nephrosis may contribute to proximal sodium
retention by increasing the proximal Naþ,Kþ-ATPase
activity directly or through the increase in the apical
membrane Naþ/Hþ exchanger NHE3 protein.
On the basis of these considerations we decided to
study the relative importance of the lack of renal
dopamine in PAN-treated rats on the proximal tubular
Naþ,Kþ-ATPase activity and on the enhanced sodium
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Fig. 7. Naþ,Kþ-ATPase activity in proximal tubules of PAN and
control rats after fenoldopam (10mg/kg bw/min) or vehicle infusion,
7 days after injection, expressed as the rate of Pi release. Bars
represent means of 6–10 experiments per group and error bars
represent SE. *P<0.01, signiﬁcantly different from values in
vehicle-treated rats; #P<0.05, signiﬁcantly different from values in
corresponding control rats.
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retention. Since the natriuresis due to the direct
inhibitory effect of tubular transport by dopamine is
mainly mediated by D1-like receptors and is evident in
volume-expanded states but not in sodium-depleted
states [8,9], we decided to evaluate the effect of the
infusion of the D1-like agonist fenoldopam during an
acute VE with saline, in conditions of greatest sodium
retention and ascites accumulation (day 7). When the
PAN-treated and control rats were submitted to VE
on day 7, we found that the proximal tubular Naþ,Kþ-
ATPase activity was similar between the two groups. It
should be mentioned, however, that the PAN-treated
rats had a decreased whole-animal glomerular ﬁltration
rate (GFR), as revealed by the signiﬁcantly lower
creatinine clearance compared with control animals.
Given the reduced total kidney GFR, the ‘normal’
proximal tubular Naþ,Kþ-ATPase activity suggests
a heightened level of proximal sodium absorption
in PAN-treated rats reﬂecting a reset level of glomer-
ulotubular balance. Our results of increased and
insufﬁciently suppressible proximal tubular sodium
reabsorption by volume loading in PAN nephrosis
agree well with the ﬁndings of others [20]. As
the inhibition of proximal tubular Naþ,Kþ-ATPase
activity by fenoldopam was more pronounced in PAN-
treated rats than in control animals, it seems reasonable
to postulate that the reduced renal dopamine tonus
may contribute, at least in part, to proximal sodium
retention during PAN nephrosis.
One should recall that the relative increase of sodium
reabsorption in the proximal tubules and the reset of
the glomerulotubular balance remain controversial in
PAN nephrosis. Actually, other investigators showed
that sodium reabsorption was decreased in the prox-
imal tubules of experimental nephrotic syndrome and
that the correction of the GFR following saralazin
infusion did not change the renal sodium retention and
urinary sodium excretion [21]. It should be mentioned,
however, that those studies were performed with the
unilateral model of PAN-induced nephrosis using a
different rat strain and only evaluated superﬁcial
nephrons. Moreover, the plasma protein concentration
remained unaltered in the study from Ichikawa et al.,
whereas in the present study the plasma protein
concentration was reduced on day 7 in the PAN-
treated rats, suggesting that alterations in plasma
composition may also contribute to increase proximal
sodium reabsorption.
Besides the proximal tubule, dopamine can also
inhibit sodium reabsorption in both the thick ascending
limb and the cortical collecting duct [8]. However,
despite the enhanced sensitivity of proximal tubular
Naþ,Kþ-ATPase activity to inhibition by fenoldopam,
the urinary sodium excretion was not signiﬁcantly
altered in PAN-treated rats during the administration
of the D1 agonist whereas the natriuresis in control
rats increased by 20–80%. Thus, one can hypothesize
that the fenoldopam-induced increase in sodium
delivery from the proximal tubules was subjected to an
enhanced reabsorption in distal nephron segments by
dopamine-independent mechanisms. This suggestion
ﬁts well with the observations showing that the cortical
collecting duct is the primary site of salt retention
in nephrotic syndrome probably due to enhanced
Naþ,Kþ-ATPase activity and to ANP resistance [1].
There is an abundance of evidence suggesting that
the natriuretic effects of ANP may be to a large extent
mediated via renal D1-like dopamine receptors [8].
Recently, it has been shown that ANP and cGMP may
recruit silent D1 dopamine receptors from the interior
of the cells towards the plasma membrane [11].
Although our study was not designed to evaluate the
relationship between ANP resistance and dopamine
in the nephrotic state, one cannot exclude that the
ANP resistance in the cortical collecting duct may be
accompanied by a decreased number of D1 receptors
available for dopamine binding in the distal tubules
which may contribute to the blunted natriuretic
response to fenoldopam observed in PAN-treated
rats. For the purpose of establishing a link between
blunted renal dopaminergic system and edema
development in PAN nephrosis, longer periods of
time will be required to address this issue in a more
complete way.
In summary, PAN-induced nephrotic syndrome is
associated with a blunted renal dopaminergic system
activity which may contribute to the relative increase
of the proximal tubular Naþ,Kþ-ATPase activity,
irrespective of the decrease in GFR. However, the lack
of renal dopamine appears not to be related to the
overall renal sodium retention in a state of proteinuria.
Acknowledgements. The authors thank the technical assistance
of Manuela Moura and Isaura Oliveira. Benedita Sampaio-Maia
was supported by Grant SFRH/BD/1479/2000 and this study was
supported by POCTI/FCB/45660/2002 from Fundac¸a˜o para a
Cieˆncia e a Tecnologia.
Conﬂict of interest statement. None declared.
References
1. Deschenes G, Doucet A. Collecting duct (Naþ/Kþ)-ATPase
activity is correlated with urinary sodium excretion in rat
nephrotic syndromes. J Am Soc Nephrol 2000; 11: 604–615
2. Plum J, Mirzaian Y, Grabensee B. Atrial natriuretic peptide,
sodium retention, and proteinuria in nephrotic syndrome.
Nephrol Dial Transplant 1996; 11: 1034–1042
3. Zolty E, Ibnou-Zekri N, Izui S, Feraille E, Favre H.
Glomerulonephritis and sodium retention: enhancement of
Naþ/Kþ-ATPase activity in the collecting duct is shared by
rats with puromycin induced nephrotic syndrome and mice with
spontaneous lupus-like glomerulonephritis. Nephrol Dial
Transplant 1999; 14: 2192–2195
4. Valentin JP, Ying WZ, Sechi LA et al. Phosphodiesterase
inhibitors correct resistance to natriuretic peptides in rats with
Heymann Nephritis. J Am Soc Nephrol 1996; 7: 582–593
5. Besse-Eschmann V, Klisic J, Nief V, Le Hir M, Kaissling B,
Ambuhl PM. Regulation of the proximal tubular sodium/proton
exchanger NHE3 in rats with puromycin aminonucleoside
(PAN)-induced nephrotic syndrome. J Am Soc Nephrol 2002;
13: 2199–2206
6. Deschenes G, Gonin S, Zolty E et al. Increased synthesis and
avp unresponsiveness of Na,K-ATPase in collecting duct from
nephrotic rats. J Am Soc Nephrol 2001; 12: 2241–2252
322 B. Sampaio-Maia et al.
7. Soares-da-Silva P. Source and handling of renal
dopamine: its physiological importance. News Physiol Sci
1994: 128–134
8. Aperia AC. Intrarenal dopamine: a key signal in the interactive
regulation of sodium metabolism. Annu Rev Physiol 2000; 62:
621–647
9. Jose PA, Eisner GM, Felder RA. Paracrine regulation of
renal function by dopamine. In: Seldin DW, Giebisch G (eds).
The Kidney Physiology and Pathophysiology. Lippincot
Williams and Wilkins, Philadelphia, 2000: 915–930
10. Bacic D, Kaissling B, McLeroy P, Zou L, Baum M, Moe OW.
Dopamine acutely decreases apical membrane Na/H exchanger
NHE3 protein in mouse renal proximal tubule. Kidney Int
2003; 64: 2133–2141
11. Holtback U, Brismar H, DiBona GF, Fu M, Greengard P,
Aperia A. Receptor recruitment: a mechanism for interactions
between G protein-coupled receptors. Proc Natl Acad Sci USA
1999; 96: 7271–7275
12. Sampaio-Maia B, Serrao P, Guimaraes JT, Vieira-Coelho MA,
Pestana M. Renal dopaminergic system activity in the rat
remnant kidney. Nephron Exp Nephrol 2005; 99: e46–55
13. Bradford MM. A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal Biochem 1976; 72:
248–254
14. Quigley JP, Gotterer GS. Distribution of (Naþ-Kþ)-stimulated
ATPase activity in rat intestinal mucosa. Biochim Biophys Acta
1969; 173: 456–468
15. Guimaraes JT, Vieira-Coelho MA, Serrao MP,
Soares-da-Silva P. Opossum kidney (OK) cells in culture
synthesize and degrade the natriuretic hormone dopamine:
a comparison with rat renal tubular cells. Int J Biochem Cell
Biol 1997; 29: 681–688
16. Soares-da-Silva P, Fernandes MH, Pestana M. Studies on the
role of sodium on the synthesis of dopamine in the rat kidney.
J Pharmacol Exp Ther 1993; 264: 406–414
17. Motulsky H, Spannard P, Neubig R. Graph Pad Prism. Graph
Pad Prism Software, San Diego, CA, 1994.
18. Eddy AA, Michael AF. Acute tubulointerstitial nephritis asso-
ciatedwith aminonucleoside nephrosis.Kidney Int 1988; 33: 14–23
19. Pestana M, Faria MS, Oliveira JG et al. Assessment of renal
dopaminergic system activity during the recovery of renal
function in human kidney transplant recipients. Nephrol Dial
Transplant 1997; 12: 2667–2672
20. Zatz R, Fujihara CK, Marcondes M. Sodium handling and
renal hemodynamics in euvolemic and volume-expanded
nephrotic rats. Braz J Med Biol Res 1986; 19: 429–438
21. Ichikawa I, Rennke HG, Hoyer JR et al. Role for intrarenal
mechanisms in the impaired salt excretion of experimental
nephrotic syndrome. J Clin Invest 1983; 71: 91–103
Received for publication: 3.4.05
Accepted in revised form: 31.8.05
Renal dopamine in PAN nephrosis 323
